This information is intended for use by health professionals
Each 5 g of powder contains:
Sodium Bicarbonate Ph Eur
Citric Acid Ph Eur
Anhydrous Sodium Carbonate Ph Eur
Each 5g of powder contains 0.85 g of sodium
The symptomatic relief of indigestion, flatulence and nausea.
For oral administration.
Adults and children aged 12 years and over:
5 g (one 5 ml spoonful of powder) or one sachet dissolved in a glass of water. Drink as symptoms occur.
A second dose may be taken after 2-3 hours.
Minimum dosing interval: 2 hours.
Maximum daily dose (MDD): 2 x relevant dosage (5 g).
Maximum duration of antacid use at MDD: 14 days.
Children under 12 years: Do not use.
The elderly can take the adult dose.
Persons on a restricted sodium diet e.g. those suffering from hypertension or congestive heart failure, should not use this product unless directed by a doctor.
Patients with impaired hepatic and renal function.
Sodium Carbonate + Sodium Bicarbonate + Citric Acid is contraindicated in patients with a prior hypersensitivity reaction to Sodium Carbonate + Sodium Bicarbonate + Citric Acid or any other ingredient of the preparation.
Do not exceed the recommended dose as excess or prolonged use may lead to alkalosis.
Treatment should be discontinued if there is no improvement in condition.
Keep out of reach and sight of children.
The acid neutralising capacity of the product may alter the absorption profile of pH specific drugs given concomittantly.
For Eno no clinical data on exposed pregnancies are available.
Animal studies on each of the active ingredients do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
Caution should be exercised when recommending to pregnant women.
Specific estimation of the frequency of adverse events for non-prescription products from post-marketing data is inherently difficult (particularly numerator data). On this basis, no estimate for MedDRA frequency categories is provided.
Gastrointestinal System SOC:
Minor gastrointestinal irritations, including belching, flatulence, and abdominal distension.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellow card.
It would be difficult to take an overdosage of the product either in the dry form or when mixed with water.
Moderate, acute overdosage may result in belching and gastro-intestinal disturbances. Treatment would be withdrawal of the product and symptomatic measures, as appropriate.
Severe acute overdosage may precipitate sodium overload (hypernatraemia or hyperosmolality) and possibly metabolic alkalosis. Symptoms may include restlessness, weakness, thirst, reduced salivation, dizziness, headache and possibly hypotension and tachycardia. Treatment would consist mainly of appropriate correction of fluid-electrolyte balance.
Acute ingestion of the neat powder may lead to gastric irritation, gas liberation and possibly stomach perforation. Treatment would be gastric lavage and general supportive and symptomatic measures.
This product is an antacid.
These react in the glass of water to
produce sodium citrate, which has antacid
buffering properties, and carbon dioxide which facilitates eructation. A slight excess of sodium bicarbonate remains with a small, direct acid neutralising contribution.
Since the antacid combination acts locally in the stomach and the components are all dissolved, a consideration of their systemic bioavailability and pharmacokinetic behaviour is not appropriate to safety and efficacy considerations.
Residual sodium and citrate ions available for absorption are safely handled by the body and excreted by normal metabolic routes.
Preclinical safety data on these active ingredients in the literature, have not revealed any pertinent and conclusive findings which are of relevance to the recommended dosage and use of the product.
Clear, flint glass jar (150 g) with polythene, tamper-evident, Jay-cap closure.
Sachet of laminate comprising 40 gsm paper/12 gsm low density polythene/0.012 mm aluminium foil/23 gsm low density polythene, containing 5 g of powder. The sachets (1 or 10) may be contained in a boxboard carton.
GlaxoSmithKline Consumer Healthcare (UK) Trading Limited
980 Great West Road
10 June 1991 / 1 December 1998
28th February 2017